---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-095195"
form_type: "8-K"
ticker: "CVKD"
cik: "0001937993"
company_name: "Cadrenal Therapeutics, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:56:51.262917+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cadrenal Therapeutics Q3 2024 cash $11.3M, raises $9.8M from ATM and warrants

## Summary
- Q3 2024 operating expenses $2.5M including $0.3M non-cash; cash used in operations $2.2M.
- Raised $5.1M via ATM and $4.7M from warrant exercises, totaling $9.8M.
- FDA discussions advancing on tecarfarin Phase 3 LVAD trial protocol; Abbott collaboration ongoing.
- CDMO completed readiness to supply API and clinical trial materials under cGMP.
- Joined Anticoagulation Forum Corporate Council to engage 15,000 healthcare professionals.

## SEC filing metadata
- accession: 0001213900-24-095195
- form_type: 8-K
- ticker: CVKD
- cik: 0001937993
- company_name: Cadrenal Therapeutics, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937993/000121390024095195/0001213900-24-095195-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937993/000121390024095195/ea0220315-8k_cadrenal.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-095195
- JSON: https://secwatch.observer/filing/0001213900-24-095195.json
- Plain text: https://secwatch.observer/filing/0001213900-24-095195.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.